Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia

• Main Authors: Yazed AlRuthia (Author), Khaled Hani Aburisheh (Author), Sondus Ata (Author), Raghad Bin Salleeh (Author), Shahad B. Alqudhibi (Author), Raghad B. Alqudhibi (Author), Ziad Alkraidis (Author), Hala Humood Alkhalaf (Author), Abdulrahman Abdullah Almogirah (Author), Muhammad Mujammami (Author), Reem Al Khalifah (Author)
• Format: Book
• Published: Elsevier, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Semaglutide, a Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA), is often prescribed for managing type 2 diabetes, particularly in cases unresponsive to other hypoglycemic agents. Despite its popularity, the real-world efficacy and cost-effectiveness of Semaglutide relative to other...